AMAG Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
AMAG AMAG Pharmaceuticals Inc
HCI Hci Group Inc
PSF Cohen & Steers Select Preferred and Income Fund
PJT PJT Partners Inc
ALK Alaska Air Group Inc
RS Reliance Steel & Aluminum Co
HFWA Heritage Financial Corp
MET MetLife Inc
KALU Kaiser Aluminum Corp
STBA S&T Bancorp Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

Closing Price
$13.67
Day's Change
0.01 (0.07%)
Bid
--
Ask
--
B/A Size
--
Day's High
13.67
Day's Low
13.61
Volume
(Light)
Volume:
723,563

10-day average volume:
1,312,130
723,563

Manchester United PLC Announces Fourth Quarter Fiscal 2020 Earnings Report Date

9:00 am ET October 9, 2020 (BusinessWire) Print

Manchester United plc (NYSE:MANU), one of the most popular and successful sports teams in the world, playing one of the most popular spectator sports on Earth, today announced that it will report results for the fourth quarter fiscal 2020 period ended 30 June 2020 on Wednesday, 21 October, 2020 at approximately 7:00 AM EDT, followed by a conference call at 8:00AM EDT to discuss the results.

A live, listen-only webcast of the conference call will be available on Manchester United's investor relations website at http://ir.manutd.com. Thereafter, a replay of the webcast will be available for thirty days.

About Manchester United

Manchester United is one of the most popular and successful sports teams in the world, playing one of the most popular spectator sports on Earth. Through our 142-year football heritage we have won 66 trophies, enabling us to develop what we believe is one of the world's leading sports and entertainment brands with a global community of 1.1 billion fans and followers. Our large, passionate and highly engaged fan base provides Manchester United with a worldwide platform to generate significant revenue from multiple sources, including sponsorship, merchandising, product licensing, broadcasting and matchday initiatives which in turn, directly fund our ability to continuously reinvest in the club.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201009005296/en/

SOURCE: Manchester United plc

Investor Relations: 
Corinna Freedman
Head of Investor Relations
+44 161 868 8431
Corinna.Freedman@manutd.co.uk

Media Relations: 
Charlie Brooks
Director of Communications
+44 161 868 8148
charlie.brooks@manutd.co.uk
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.